• First Australian clinical site activated for RC220 Phase 1 trial
• Trial to provide safety, pharmacokinetic, and biomarker data on RC220 in combination with doxorubicin
• Preclinical studies show RC220 enhances anticancer activity of doxorubicin

Race Oncology Ltd has announced the site activation of Southside Cancer Care Centre (Miranda, NSW) after receiving governance approval, enabling the commencement of patient enrolment for its Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumours patients. This follows the receipt of human ethics approval, undertaking site initiation, and completion of all documentation. The Phase 1 trial will be open label and conducted across multiple sites in Australia, Hong Kong and South Korea. The trial will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose (MTCD) in combination with doxorubicin, and effects on a range of clinical biomarkers including m6A RNA. After an interim analysis, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. The Phase 1 trial will use a Bayesian design enabling greater trial flexibility and speed. Preclinical studies by Race Oncology have identified enhancement of the cancer killing activity of doxorubicin by the active anticancer agent in RC220 in 85% of 143 diverse cancer cell lines screened.

Race Oncology is advancing RC220 to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where they hope to deliver cardioprotection and enhanced anticancer activity in solid tumours. Race is also exploring RC220 as a low-intensity treatment for acute myeloid leukaemia.